Health · Medical Research · 6 hrs ago
Recurrent IDH-mutant brain tumors develop different genetic changes
Researchers compared tumor samples from 183 people with IDH-mutant gliomas, a group of brain cancers that almost always return after treatment.
The samples were taken before and after recurrence, allowing researchers to track genetic changes over time.
Oligodendrogliomas often gained new mutations that can drive tumor growth, while astrocytomas more often gained or lost large stretches of DNA.
The chemotherapy drug temozolomide also appeared to leave distinct genetic marks in recurrent tumors.
Some changes were linked to shorter survival after recurrence, including major chromosome changes in astrocytomas and growth-related changes in oligodendrogliomas.
The findings matter because they may help explain why tumors become resistant to treatment and support care tailored to each tumor type.
Researchers hope the findings will guide more tailored treatments, though the study focused on changes after radiation and chemotherapy.
An international study found that IDH-mutant gliomas develop distinct genetic changes when they recur after treatment.
Researchers compared tumor samples collected before and after recurrence from 183 patients.
Oligodendrogliomas tended to acquire new mutations in genes that drive tumor growth, while astrocytomas more often developed large-scale chromosomal changes.
Some recurring genetic changes were associated with poorer outcomes.
The findings, published in Nature, may help researchers tailor future treatments to tumor types and their genetic changes.
- Who
- Researchers from The Jackson Laboratory, Yale University and collaborators across 10 countries.
- What
- The study found that recurrent IDH-mutant gliomas develop different genetic changes depending on tumor subtype.
- When
- The findings were published on October 14, 2026.
- Where
- The study analyzed samples collected across North America, Europe, Asia, Australia and South America.
- Why
- The research aimed to understand how these tumors change after treatment and recurrence, including changes that may be linked to therapy resistance.
This story does not have two clearly opposing sides.
The FDA approved the IDH inhibitor vorasidenib for certain patients with these tumors.
The study findings were published in Nature.
- Patients studied
- 183
- Samples collected through
- More than 500 surgeries
- Research consortium
- Glioma Longitudinal Analysis (GLASS) Consortium
- Oligodendroglioma pattern
- New mutations in genes that help drive tumor growth
- Astrocytoma pattern
- Large-scale chromosomal changes, including gains and losses of DNA
- FDA approval
- Vorasidenib approved for certain patients in 2024
What people are saying
IDH-mutant gliomas are rare, which makes them challenging to study. Through this international collaboration, we were able to gather enough samples to characterize the most common ways each type of IDH-mutant glioma changes when it recurs